axial spondyloarthritis research hub

A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis

This study is looking at a new medicine called sonelokimab for people with a type of arthritis affecting the spine, called axial spondyloarthritis. It aims to see how the medicine might reduce inflammation in the back and hips over 12 weeks, using special scans.

axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis

This study looks into how a special liquid and food diet (Partial Enteral Nutrition or PEN) might affect gut health and inflammation in people with axial spondyloarthritis (axSpA). Researchers want to see if this diet can help improve gut bacteria and reduce inflammation, similar to how it works in some bowel conditions.

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

This study is looking at a new medication, filgotinib, for people with active axial spondyloarthritis (axSpA). We want to see if it helps reduce symptoms and is safe, comparing different doses to a dummy pill.

Walking Football for Axial Spondyloarthritis

This study looks at whether Walking Football is a safe and helpful exercise for people with axial spondyloarthritis (axSpA), a condition causing back pain and stiffness. It aims to see if it improves health, helps people stay active, and connects them with others.

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

This study looks at a medicine called Bimekizumab for long-term safety and how well it works in people with a type of arthritis affecting the spine, including Ankylosing Spondylitis. It's for people who have already been in related Bimekizumab studies.

Advanced Sensor Based Functional ASsessmenTs in Axial Spondyloarthritis

This study looks at how new treatments for a type of arthritis called axial spondyloarthritis affect back movement. We're using small sensors and MRI scans to see if treatments improve stiffness and movement in the spine.

British Axial Spondyloarthritis Inception Cohort

This study looks at how a condition called axial spondyloarthritis (axSpA) affects people in the UK. We want to understand how quickly people are diagnosed, how their health changes over time, and the impact it has on their lives and work.

A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

This study looks at how much of the medicine, Bimzelx, gets into breast milk. It's for mothers with conditions like psoriasis or arthritis who are treated with Bimzelx, to understand if it's safe for their babies.

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)

This study looks at how a drug called Rinvoq (upadacitinib) affects people with a type of arthritis called axial spondyloarthritis who also experience recurrent eye inflammation (uveitis). It aims to see if Rinvoq can reduce flare-ups of this eye condition.

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period

Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE

Rapid pain control in Ixekizumab targeted axial spondyloarthritis

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants with Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.